Float Short %

0.7

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

4.34

Price

5.33

Target Price

Analyst Recom

Performance Q

-18.26

Relative Volume

0.2

Beta

1.45

Ticker: PULM

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-07	PULM	6.78	N/A	N/A	0
2025-07-08	PULM	6.56	N/A	N/A	0
2025-07-09	PULM	6.56	N/A	N/A	0
2025-07-10	PULM	6.455	N/A	N/A	0
2025-07-11	PULM	6.4387	N/A	N/A	0
2025-07-14	PULM	6.55	N/A	N/A	0
2025-07-15	PULM	6.16	N/A	N/A	0
2025-07-16	PULM	6.15	N/A	N/A	0
2025-07-17	PULM	6.49	N/A	N/A	0
2025-07-18	PULM	6.21	N/A	N/A	0
2025-07-21	PULM	6.07	N/A	N/A	0
2025-07-22	PULM	6.09	N/A	N/A	0
2025-07-23	PULM	6.02	N/A	N/A	0
2025-07-24	PULM	5.61	N/A	N/A	0
2025-07-25	PULM	5.63	N/A	N/A	0
2025-07-28	PULM	5.26	N/A	N/A	0
2025-07-29	PULM	5.36	N/A	N/A	0
2025-07-30	PULM	5.57	N/A	N/A	0
2025-07-31	PULM	5.63	N/A	N/A	0
2025-08-01	PULM	5.33	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-07	PULM	6.78	-	-	-4.34
2025-07-08	PULM	6.56	-	-	-4.34
2025-07-09	PULM	6.51	-	-	-4.34
2025-07-10	PULM	6.44	-	-	-4.34
2025-07-11	PULM	6.31	-	-	-4.34
2025-07-14	PULM	6.55	-	-	-4.34
2025-07-15	PULM	6.16	-	-	-4.34
2025-07-16	PULM	6.20	-	-	-4.34
2025-07-17	PULM	6.33	-	-	-4.34
2025-07-18	PULM	6.27	-	-	-4.34
2025-07-21	PULM	6.28	-	-	-4.34
2025-07-22	PULM	6.09	-	-	-4.34
2025-07-23	PULM	6.02	-	-	-4.34
2025-07-24	PULM	5.61	-	-	-4.34
2025-07-25	PULM	5.62	-	-	-4.34
2025-07-28	PULM	5.28	-	-	-4.34
2025-07-29	PULM	5.27	-	-	-4.34
2025-07-30	PULM	5.57	-	-	-4.34
2025-07-31	PULM	5.63	-	-	-4.34
2025-08-01	PULM	5.33	-	-	-4.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-07	PULM	0	-2.97	0.84
2025-07-08	PULM	0	-2.97	0.84
2025-07-09	PULM	0	-2.97	0.84
2025-07-10	PULM	0	-2.97	0.84
2025-07-11	PULM	0	-2.97	0.46
2025-07-14	PULM	0	-2.97	0.46
2025-07-15	PULM	0	-2.97	0.46
2025-07-16	PULM	0	-2.97	0.46
2025-07-17	PULM	0	-2.97	0.46
2025-07-18	PULM	0	-2.97	0.46
2025-07-21	PULM	0	-3.04	0.46
2025-07-22	PULM	0	-3.04	0.46
2025-07-23	PULM	0	-3.04	0.46
2025-07-24	PULM	0	-3.04	0.46
2025-07-25	PULM	0	-3.04	0.70
2025-07-28	PULM	0	-3.03	0.70
2025-07-29	PULM	0	-3.03	0.70
2025-07-30	PULM	0	-3.03	0.70
2025-07-31	PULM	0	-3.03	0.70
2025-08-01	PULM	0	-3.03	0.70
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-1.04

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-3.03

Beta

1.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

91.2

Max Drawdown 5-Year %

-96.9

Target Price

P/E

Forward P/E

PEG

P/S

10.14

P/B

2.73

P/Free Cash Flow

EPS

-3.34

Average EPS Est. Cur. Y

-4.34

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-634.67

Relative Volume

0.2

Return on Equity vs Sector %

-194.3

Return on Equity vs Industry %

-175.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Pulmatrix, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 2

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

stock quote shares PULM – Pulmatrix Inc Stock Price stock today

news today PULM – Pulmatrix Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PULM – Pulmatrix Inc yahoo finance google finance

stock history PULM – Pulmatrix Inc invest stock market

stock prices PULM premarket after hours

ticker PULM fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PULM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y